Stockwatch

Date	Sym	Type	Headline
2024-04-24 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
2024-04-23 07:00	UU:NBIX	News Release200	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
2024-04-16 16:01	UU:NBIX	News Release200	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
2024-04-10 16:01	UU:NBIX	News Release200	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
2024-04-03 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
2024-03-28 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
2024-03-11 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
2024-02-27 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Participate at Investor Conferences in March
2024-02-07 07:00	UU:NBIX	News Release200	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
2024-01-17 16:16	UU:NBIX	News Release200	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
2024-01-02 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 16:01	UU:NBIX	News Release200	Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
2023-12-01 07:00	UU:NBIX	News Release200	Neurocrine Biosciences to Host Analyst Day on December 5, 2023
2023-11-13 07:00	UU:NBIX	News Release200	Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
2023-11-09 16:01	UU:NBIX	News Release200	Neurocrine Biosciences Provides Development Pipeline Update
2023-11-08 16:05	UU:NBIX	News Release200	Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
2023-11-08 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
2023-11-02 08:30	UU:NBIX	News Release200	Neurocrine Biosciences ‚ ® Presents INGREZZA ‚ ® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
2023-10-31 07:00	UU:NBIX	News Release200	Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-10-10 16:01	UU:NBIX	News Release200	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
2023-10-05 07:00	UU:NBIX	News Release200	Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
2023-09-21 09:15	UU:NBIX	News Release200	Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
2023-09-14 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA ‚ ® (valbenazine) Oral Granules Sprinkle Formulation
2023-09-12 07:30	UU:NBIX	News Release200	Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
2023-09-11 19:01	UU:NBIX	News Release200	Sosei Heptares ¢ € ™ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
2023-09-11 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
2023-08-31 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
2023-08-29 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders ‚ ® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA ‚ ® (valbenazin
2023-08-28 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Presents New INGREZZA ‚ ® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
2023-08-18 16:34	UU:NBIX	News Release200	Neurocrine Biosciences Announces FDA Approval of INGREZZA ‚ ® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
2023-08-01 07:00	UU:NBIX	News Release200	Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
2023-07-11 16:05	UU:NBIX	News Release200	Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
2023-07-11 16:01	UU:NBIX	News Release200	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
2023-06-15 08:30	UU:NBIX	News Release200	Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023
2023-06-08 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-02 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Presents INGREZZA ‚ ® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate
2023-05-19 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Announces Publication of Full KINECT ¢ „ ¢-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
2023-05-15 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Presents INGREZZA ‚ ® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Soci
2023-05-12 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
2023-05-03 07:30	UU:NBIX	News Release200	Neurocrine Biosciences Reports First Quarter 2023 Financial Results
2023-05-02 16:01	UU:NBIX	News Release200	Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
2023-05-01 08:30	UU:NBIX	News Release200	Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week